Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Up 12.7% – Here’s Why

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)’s stock price rose 12.7% during mid-day trading on Wednesday . The stock traded as high as $8.15 and last traded at $8.15. Approximately 9,399 shares traded hands during mid-day trading, an increase of 87% from the average daily volume of 5,025 shares. The stock had previously closed at $7.2302.

Finch Therapeutics Group Trading Up 12.7%

The firm has a market cap of $13.09 million, a P/E ratio of -0.92 and a beta of 1.18. The firm has a 50-day simple moving average of $9.90 and a 200-day simple moving average of $12.30.

About Finch Therapeutics Group

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.